EP0083820A1 - Disinfecting solutions for hydrophilic contact lenses - Google Patents
Disinfecting solutions for hydrophilic contact lenses Download PDFInfo
- Publication number
- EP0083820A1 EP0083820A1 EP82201665A EP82201665A EP0083820A1 EP 0083820 A1 EP0083820 A1 EP 0083820A1 EP 82201665 A EP82201665 A EP 82201665A EP 82201665 A EP82201665 A EP 82201665A EP 0083820 A1 EP0083820 A1 EP 0083820A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- acid
- lenses
- sodium
- fatty acid
- disinfecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000249 desinfective effect Effects 0.000 title claims abstract description 27
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 33
- 239000000194 fatty acid Substances 0.000 claims abstract description 33
- 229930195729 fatty acid Natural products 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 27
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 24
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000243 solution Substances 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 51
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 29
- 239000002253 acid Substances 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 238000004140 cleaning Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 10
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000002738 chelating agent Substances 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000644 isotonic solution Substances 0.000 claims description 3
- 150000007942 carboxylates Chemical group 0.000 claims description 2
- 235000021588 free fatty acids Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 21
- 238000003795 desorption Methods 0.000 abstract description 16
- 230000000845 anti-microbial effect Effects 0.000 abstract description 10
- 206010070834 Sensitisation Diseases 0.000 abstract description 3
- 230000007794 irritation Effects 0.000 abstract description 3
- 230000008313 sensitization Effects 0.000 abstract description 3
- 235000002639 sodium chloride Nutrition 0.000 description 30
- 159000000000 sodium salts Chemical class 0.000 description 19
- -1 polyoxyethylene stearate Polymers 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 229960002446 octanoic acid Drugs 0.000 description 10
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 10
- 239000004599 antimicrobial Substances 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 239000000882 contact lens solution Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229960003260 chlorhexidine Drugs 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 4
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 3
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 3
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 235000011083 sodium citrates Nutrition 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 239000001540 sodium lactate Substances 0.000 description 3
- 229940005581 sodium lactate Drugs 0.000 description 3
- 235000011088 sodium lactate Nutrition 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 235000011008 sodium phosphates Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical compound CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001616 Polymacon Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- HJZKOAYDRQLPME-UHFFFAOYSA-N oxidronic acid Chemical compound OP(=O)(O)C(O)P(O)(O)=O HJZKOAYDRQLPME-UHFFFAOYSA-N 0.000 description 2
- 229960004230 oxidronic acid Drugs 0.000 description 2
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229960005480 sodium caprylate Drugs 0.000 description 2
- LHYPLJGBYPAQAK-UHFFFAOYSA-M sodium;pentanoate Chemical compound [Na+].CCCCC([O-])=O LHYPLJGBYPAQAK-UHFFFAOYSA-M 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- VMKOFRJSULQZRM-UHFFFAOYSA-N 1-bromooctane Chemical compound CCCCCCCCBr VMKOFRJSULQZRM-UHFFFAOYSA-N 0.000 description 1
- XPSXBEJFSQZTBS-UHFFFAOYSA-N 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate N-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=C)C(=O)OCCO.CC(=O)CC(C)(C)NC(=O)C=C.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C XPSXBEJFSQZTBS-UHFFFAOYSA-N 0.000 description 1
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- JYXGIOKAKDAARW-UHFFFAOYSA-N N-(2-hydroxyethyl)iminodiacetic acid Chemical compound OCCN(CC(O)=O)CC(O)=O JYXGIOKAKDAARW-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JQDZNJOONPXQSL-UHFFFAOYSA-N [acetyloxy-[2-(diacetyloxyamino)ethyl]amino] acetate;sodium Chemical compound [Na].CC(=O)ON(OC(C)=O)CCN(OC(C)=O)OC(C)=O JQDZNJOONPXQSL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000012431 aqueous reaction media Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000005702 oxyalkylene group Chemical group 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- UDWXLZLRRVQONG-UHFFFAOYSA-M sodium hexanoate Chemical compound [Na+].CCCCCC([O-])=O UDWXLZLRRVQONG-UHFFFAOYSA-M 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
- NMTDPTPUELYEPL-UHFFFAOYSA-M sodium;heptanoate Chemical compound [Na+].CCCCCCC([O-])=O NMTDPTPUELYEPL-UHFFFAOYSA-M 0.000 description 1
- LTOCMXUTASYUOC-UHFFFAOYSA-M sodium;nonanoate Chemical compound [Na+].CCCCCCCCC([O-])=O LTOCMXUTASYUOC-UHFFFAOYSA-M 0.000 description 1
- ZOOPHYLANWVUDY-UHFFFAOYSA-M sodium;undecanoate Chemical compound [Na+].CCCCCCCCCCC([O-])=O ZOOPHYLANWVUDY-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/02—Anionic compounds
- C11D1/04—Carboxylic acids or salts thereof
Definitions
- the present invention relates to aqueous solutions used for the cleaning, disinfecting and storing of hydrophilic soft contact lenses.
- Hydrophilic or partially hydrophilic plastic materials have been used in making "soft" contact lenses.
- U.S. Patents 3,503,393 and 2,976,576 describe processes for producing three dimensional hydrophilic polymers of polyhydroxyethylmethacrylate in aqueous reaction media; these polymers have low degrees of.cross-linking in their hydrogel structure and have the appearance of elastic, soft, transparent hydrogels.
- Soft contact lenses have also been made out of silicone and other optically suitable flexible materials. The popularity of soft contact lenses is growing rapidly. The major virtues of these lenses are their softness (providing comfort to the wearer), permeability to gases, and their optical suitability.
- the hydrophilic lenses are particularly useful for ophthalmological applications due to their ability to absorb water with a concomitant swelling to a soft mass of extremely good mechanical strength, their complete transparency, and their ability to retain shape and dimension when equilibrated in a given fluid.
- Hard contact lenses do not absorb appreciable amounts of water (i.e., only from about 0.1 to about 0.4%) and thus the use of conventional preservatives and antimicrobials generally does not present a problem in the hard contact lens field. Disinfecting of soft contact lenses is frequently carried out by boiling the lenses in normal saline, an inconvenient and cumbersome procedure. Furthermore, wearers of soft contact lenses are often warned that solutions designed for hard contact lenses should not be used with soft lenses, since the preservatives in such solutions will be absorbed and even concentrated by the soft lenses and may seriously damage the contact lens and/or the eye of the user.
- Thimerosal (sodium ethylmercurithiosalicylate) and chlorhexidine are well-known preservatives, frequently used in contact lens disinfecting solutions. See, for example, Handbook of Nonprescription Drugs, 5th ed., American Pharmaceutical Association, 1977, pages 236-247, and U.S. Reissue Patent 29,693, Phares, reissued July 4, 1978.
- the use of certain organic acids as components in contact lens cleaning solutions has been disclosed in the art.
- Japanese Specification 78-28,922, Allergan Pharmaceuticals, issued August 17, 1978 describes contact lens cleaning solutions containing polyoxyethylene stearate.
- French Patent 2,400,906, issued March 23, 1979 describes the use of ascorbic acid and sodium ascorbate in contact lens cleaning solutions.
- JAMA 143, 226(1950) discloses that the lower fatty acids have been shown to be of value in the treatment of external infections of the eyes. Specifically, sodium propionate was found effective against bacteria causing common occular and fungal infections, including staphylococcus and Pseudomonas aerugnosa.
- Copending Canadian Patent 1,098,039, Stone, issued March 24, 1981 describes the use of octanoic acid as a broad spectrum antimicrobial agent in intravenous, nutrient and dialysis solutions; these solutions typically contain electrolytes, such as sodium chloride. The antimicrobial benefits of maintaining a solution pH between about 3.5 and 6.0 are taught.
- an object of the present invention to provide an effective cleaning, disinfecting and storing solution for soft contact lenses characterized by rapid and complete desorption of the antimicrobial material from the lens.
- the present invention relates to aqueous isotonic solutions having a pH between about 3.5 and 6.5, suitable for cleaning, disinfecting and storing hydrophilic soft contact lenses, comprising:
- the present invention also encompasses a method for cleaning and disinfecting hydrophilic soft contact lenses wherein said lenses are contacted with an effective amount of a C 5 -C 12 fatty acid, especially octanoic acid.
- compositions of the present invention are formulated as aqueous isotonic solutions which contain three basic components: (1) a C S -C 12 fatty acid or a mixture of such acids; (2) a water-soluble, ocular tissue- compatible salt; and (3) a calcium chelator. These components are dissolved.iw water which has been prepared in . such a way so as to be compatible for use in the eye (e.g., pyrogen-free water).
- the solutions of the present invention provide the following advantages over the currently-used soft contact lens disinfecting solutions: (1) rapid and broad spectrum cidal activity; (2) rapid and complete desorption_of the antimicrobial agent from the contact lens material, thereby minimizing eye sensitization and irritation problems; and (3) usage flexibility, since the solutions of the present invention may be used interchangeably in both hot and cold sterilization procedures without causing the lenses to turn opaque.
- safe and effective amount means sufficient fatty acid component, comprising. at least the minimum lethal concentration in aqueous solution of the free acid form of the particular fatty acid being used, to provide the desired antimicrobial benefit in the context of and under the conditions utilized in the soaking and disinfecting of hydrophilic soft contact lenses, not to exceed an amount which is compatible with the compositions herein and safe for use in conjunction with ocular tissue.
- “Pharmaceutically-acceptable” or “pharmacologically-acceptable”, as used herein, means that the fatty acid compound and other ingredients used in the. compositions are suitable for use in contact with the tissue of humans, particularly ocular tissue, without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
- compositions of this invention means that various other compatible components including both active and inert ingredients, can be conjointly employed in the compositions of this invention, as long as. the critical fatty acid compounds are used in the manner disclosed.
- comprising thus encompasses and includes the more restrictive terms “consisting of” and “consisting essentially of”.
- ком ⁇ онент herein is meant that the components of the present invention are capable of being commingled without interacting in a manner which would substantially decrease the efficacy of the fatty acids under ordinary use conditions.
- fatty acids useful in the present invention include those having from about 5-to about 12 carbon atoms; carboxylic acids outside of this range are significantly- less effective as antimicrobial agents. These materials, themselves, are well-known in the art.
- octanoic acid is an oily liquid having a boiling point of 239.7°C and a melting point of 16.7°C; it is very. slightly soluble in water (0.068 grams/100 grams at 20°C) and freely soluble in alcohol, chloroform, carbon disulfide, petroleum ether and glacial acetic acid.
- Octanoic acid may be prepared from 1-heptene, Dupont, et al., Compt. Rend. 240, 628 (1958),- or by the oxidation of octanol, Langenbeck, et al., Ber., 89, 202 (1956).
- octanoic acid is described in U.S. Patent 2,821,532, issued in 1958 and assigned to GAF, and U.S. Patent 3,053,869, issued in 1960 and assigned to Standard Oil of Indiana. See also Fatty Acids, part 1, K.S. Merkley, Editor (Interscience,New York, 2nd E d., 1960) pages 34-38. Decanoic acid is a crystalline solid having a melting point of 31.4°C; it is practically insoluble in water. See Fatty Acids, part l, supra, pages 34-39. Decanoic acid may be prepared from octyl- bromide, Shishido, et al., J. Am. Chem. Soc. 81, 5817 (1959), and.U.S. Patent 2,918,494, issued in 1959 and assigned to Ethyl Corp.
- the fatty acid component used in the present invention be a C 5 -C 12 non-aromatic carboxylic acid, such as n-pentanoic, n-hexanoic, n-heptanoic, n-octanoic, n-nonanoic, n-decanoic, n-undecanoic, or n-dodecanonic acid.
- Preferred fatty acid materials for use in the present invention contain from 6 to 10 carbon atoms, with octanoic and decanoic acid being particularly preferred. Mixtures of the above fatty acid materials may also be used, as may salts of the fatty acids, provided that the pH criteria for the compositions, as described below, are met.
- compositions of the present invention contain from about 0.001% to about 3%, preferably from about 0.01% to about 1.5% of the fatty acid materials.
- the compositions are formulated to have a pH of no greater than about 6.5 and no less than about 3.5, preferably the pH falls between about 5 and about 6.5. At pH's above this range, the antimicrobial performance of the composition falls off significantly; obviously a pH which is too low (acidic) would not be suitable for use in an ocular context.
- Compatible acidic or basic ingredients may be used to adjust the pH of the compositions to the desired range.
- the solutions of the present invention must also contain at least one water-soluble salt, compatible with ocular tissue, sufficient in amount to provide a solution salt content equivalent to from about 0.5% to about 1.8% sodium chloride.
- the purpose of this water-soluble salt is to make the solution isotonic. Hypotonic solutions (for example, tap water) will cause the contact lens to adhere too tightly to the cornea, while a hypertonic solution (for example, excess saline) will result in stinging, lacri- mation and red eyes. Mixtures of water-soluble salts may be used as long as the isotonicity of the solution is maintained.
- water-soluble salts useful in the present invention include sodium chloride, sodium citrate, sodium lactate, sodium phosphate, the sodium salts of the fatty acids defined above (such as sodium octanoate), and mixtures thereof, with sodium chloride being especially preferred.
- compositions of the present invention also contain from about 0.01% to about 2%, preferably from about 0.05% to about 1.5% of a calcium chelator component.
- This chelating agent is used to prevent metal ions, such as calcium ions, from fixing to the surfaces of the contact lenses and for removing those metal ions which are fixed to the surfaces of the lenses. Buildup of calcium ions on the lenses may cause eye irritation.
- Useful chelating agents include aminopolycarboxylic acids (such as hydroxyethyl imino diacetic acid, nitrilo triacetic acid, ethylene diamine tetraacetic acid, hydroxyethyl ethylenediamine triacetic acid, and diethylene triamine pentacetic acid), alpha-hydroxy acids (such as citric acid, tartaric acid, and gluconic acid), and condensed phosphates and phosphonates.
- the preferred chelating agents for use in the present invention are ethylenediamine tetraacetic acid'and pharmaceutically-acceptable salts thereof, especially sodium ethylenediamine tetracetate.
- Other useful calcium chelating components include ethane-l-hydroxy-l,l-diphos- phonic acid, methane diphosphonic acid, hydroxy methane disphosphonic acid and mixtures thereof.
- compositions of the present invention may optionally contain from about 0.01% to about 5% of a pharmacologically-acceptable buffer.
- ophthalmologically-physiologically acceptable buffers which may be used in the present invention include combinations of boric acid and its sodium salt, phosphoric acid and its sodium salts, citric acid and its sodium salts, lactic acid its sodium salt, amino acids (such as glycine or glutamic acid) and their sodium salts, and maleic acid and its sodium salt.
- compositions of the present invention may additionally contain from about 0.01% to about 5% of a pharmacologically-acceptable viscosity control agent, such as polyvinyl alcohol, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, soluble polyhydroxyethyl methacrylate (known as poly hema), polyvinyl pyrollidone, and mixtures thereof.
- a pharmacologically-acceptable viscosity control agent such as polyvinyl alcohol, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, soluble polyhydroxyethyl methacrylate (known as poly hema), polyvinyl pyrollidone, and mixtures thereof.
- the solutions of the present invention may also contain from about 0.01% to about 5% of a pharmacologically- and ophthalmologically-acceptable surfactant, particularly a nonionic surfactant.
- a pharmacologically- and ophthalmologically-acceptable surfactant particularly a nonionic surfactant.
- These surfactants are especially useful when the solutions are formulated to clean the lenses as well as to sterilize them.
- the surfactants which may be employed in the present invention must be completely miscible with water at the concentrations employed and must provide a clear solution.
- the surfactant must be stable under the disinfecting conditions, must not act adversely with the soft contact lens, nor with other materials present in the solution and, finally, must not irritate the eye.
- the surfactant preferably is not absorbed by the soft contact lens material, while being capable of solublizing the proteinaceous and lipid materials adsorbed onto the lens and, further, preventing redeposition during sterilization and subsequent storage.
- Useful nonionic surfactants are well-kndwn in the art and include, but are not limited to, hydroxyalkylated and polyoxyalkylated surfactants, such as n-hydroxyalkylated carboxamides of fatty acids of from 10 to 18 carbon atoms, preferably of from 12 to 14 carbon atoms, and having 0 or 1 sites of olefinic unsaturation as the only unsaturation, preferably being saturated. These compounds will normally contain two hydroxyalkyl groups of from 2 to 3 carbon atoms which.may be the same or different.
- the polyoxyalkylated nonionic surfactants may be solely comprised of ethoxy or propoxy groups or may have a polyoxyalkylene chain bonded directly or indirectly to an aliphatic chain of from 10 to 18 carbon atoms.
- the alkyl- containing group may be a sorbitan ester, an alkylphenyl, alkyl, carboxylic acid, or the like.
- the polyoxyalkylene chain may be a homo-oligomer or co-oligomer, with the homo-oligomer normally being ethyleneoxy groups and the co-oligomer being a random or block co-oligomer of ethyleneoxy and propyleneoxy groups.
- alkyleneoxy chains will generally range on the average of from about 5 to about 60 oxyalkylene units.
- Ampholytic surfactants such as betaines having an aliphatic carbon chain bonded to nitrogen of from about 10 to 18 carbon atoms, preferably from about 10 to 14 carbon atoms, may also be used herein.
- Particularly preferred surfactants for use in the present invention include polyoxyethylenes, octylphenoxy polyethoxy ethanols, polysorbates and mixtures thereof.
- the present invention also encompasses a method for cleaning and disinfecting hydrophilic soft contact lenses Wherein the lenses are contacted with a safe and effective amount of the C S - C 12 fatty acids.
- the fatty acids will generally be in the form of an aqueous solution having a concentration of from about 1 to about 200, preferably from about 1 to about 175, millimoles of a mixture of the free fatty acid and the carboxylate (anionic) salt per liter.
- the microbiocidal activity of the C 5 -C 12 carboxylate antimicrobials used herein is directly related to the presence of their respective free acids in solution.
- the concentration of free carboxylic acid in solution, as opposed to carboxylate salt (anionic) form, is a function of the pH of the solution.
- the carboxylic acid salts can be used herein, but only as long as the pH of the solution is in the acid range so that the minimum lethal concentration (MLC) of free acid is present. Accordingly, the amount of acid or acid salt used will vary somewhat with the pH. The amount of a given acid salt or acid which will provide the MLC at a given pH will depend on the pKa of the acid. Of course, knowing the pKa, the MLC of the particular acid and the solution pH, the amount of any C 5 -C 12 acid or acid salt to be used is easily calculated. Representative MLC values are as follows: C 5 (0.11 M) ; C 6 (30 mM); C 7 (9 mM); C 8 . (3 mM); and C 9 (1mM). The compositions, described above, are preferred for use in this method. Generally, the contact lenses are contacted with the fatty acid components for periods ranging between about 5 minutes and about 12 hours, although under some circumstances, longer or shorter periods may be utilized.
- a disinfecting solution for hydrophilic contact Lenses of the present invention having the formula given below, was formulated in the following manner.
- the following quantities of materials were measured out and added to a 100 milliliter volumetric flask: 0.943 grams of sodium octanoate; 0.696 grams of monobasic sodium phosphate; 0.123 grams of dibasic sodium phosphate; 0.1 gram ethylenediamine tetraacetic acid, disodium salt; and 0.187 grams of sodium chloride. These materials were dissolved in 100 milliliters of distilled water. The resulting solution had a pH of 6.0 when measured at a temperature of 23°C.
- compositions of the present invention may also be formulated by adding about 0.5%.of a surfactant selected from polyoxyethylene, polysorbate 80, octylphenoxy (oxyethylene) ethanol,, and mixtures thereof to the composition described above.
- a viscosity control agent selected from polyvinyl alcohol, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, soluble poly hema, polyvinyl pyrollidone, and mixtures thereof may also be added to the formulation given above at a level of about 0.5%.
- compositions of the present invention may also be formulated by replacing the sodium octanoate, in the compositions described above, with an equivalent amount of a fatty acid selected from sodium pentanoate, sodium pentanoate, sodium hexanoate, sodium heptanoate, sodium nonanoate, sodium decanoate, sodium undecanoate, or sodium dodecanaote.
- a fatty acid selected from sodium pentanoate, sodium pentanoate, sodium hexanoate, sodium heptanoate, sodium nonanoate, sodium decanoate, sodium undecanoate, or sodium dodecanaote.
- the level of octanoate absorbed by Bausch & Lomb Soflens contact lenses from disinfecting solutions of the present invention, as well as the rate at which the octanoate is desorbed from the lenses was determined by the procedure described below.
- test solution used in this procedure was that described in Example I, except that the sodium octanoate was labeled using carbon-14, having a radiochemical purity of greater than 98.5%, a chemical purity of greater than 99%, and a specific activity of 164 mCi/gram.
- 35 Milliliters of the test solution was prepared.
- Four scintillation vials were filled with 5.03 ⁇ 0.03.milliliters of this solution.
- Another four vials were filled with 2.51 ⁇ 0.03 milliliters of the solution.Two vials from each set of four vials were set aside for radioassay. The remaining four vials each had a contact lens (Bausch & Lomb Soflens) submersed in it.
- each lens was removed from its vial with fine forceps.
- the lenses were gently touched to the inside walls of the vial to remove excess fluid and were not rinsed.
- the lenses were then immediately transferred to,vials containing 2.5 milliliters of a 00.9% sodium chloride solution and gently swirled.
- the lenses were again transferred to another set of vials containing 2.5 milliliters of 0.9% sodium chloride solution. This process was repeated according to the lens transfer schedule specified below.
- the desorption characteristics of a composition of the present invention were determined using a variety of hydrophilic soft contact lens materials.
- the lenses tested were Soflens made from a Polymacon polymer; Hydron made'from a Polymacon polymer; Durasoft, made from Phemfilcon A polymer; AO Soft made from Tetrafilcon A polymer; and Hydrocurve II, made from Bufilcon A polymer.
- the lenses and solutions in the Lensgard case were subjected to heat sterilization with the Bausch & Lomb Disinfecting Unit II according to the manufacturer's recommended procedures.
- the unit was allowed to cool and stand overnight and the lenses were desorbed approximately 24 hours after the initial sorption began, using the usual desorption transfer schedule.
- the test solution was not retained and submitted for radioassay for the final two lenses because of expected evaporative losses in the heat sterilization process.
- the above treatments were shown to have no significant effect on the time course or completeness-of the desorption from the Bausch & Lomb lenses.
- the ethylene diamine tetraacetic acid, disodium salt may also be replaced in whole or in part with ethane-1-hydroxy-1,1-diphosphonic acid, methane diphosphonic acid, hydroxymethane diphosphonic acid and mixtures thereof, yielding similar results.
- the antimicrobial efficacy of the composition was expressed in terms of D-values against a range of microorganisms specified by the U.S. FDA as'those which a class II contact lens solution should be effective against.
- a D-value is the time required to kill 90% of a population of microorganisms. In this-study the D-value was calculated from the amount of time required for the product to completely kill a population of about 10 5 organisms/ml.
- buffer portion of the solution i.e., the mono-and dibasic sodium phosphate components
- the buffer portion of the solution i.e., the mono-and dibasic sodium phosphate components
- the buffer portion of the solution i.e., the mono-and dibasic sodium phosphate components
- boric acid and its sodium salt citric acid and its sodium salts
- lactic acid and its sodium salt glycine or glutamic acid and their sodium salt
- maleic acid and its sodium salt or mixtures thereof.
- the ethylene diamine tetraacetic acid, disodium salt may also be replaced in whole or in part with ethane-l-hydroxy-l,l-diphosphonic acid, methane diphosphonic acid, hydroxymethane diphosphonic acid and mixtures thereof, yielding similar results.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Eyeglasses (AREA)
- Detergent Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
- The present invention relates to aqueous solutions used for the cleaning, disinfecting and storing of hydrophilic soft contact lenses.
- Hydrophilic or partially hydrophilic plastic materials have been used in making "soft" contact lenses. For example, U.S. Patents 3,503,393 and 2,976,576 describe processes for producing three dimensional hydrophilic polymers of polyhydroxyethylmethacrylate in aqueous reaction media; these polymers have low degrees of.cross-linking in their hydrogel structure and have the appearance of elastic, soft, transparent hydrogels. Soft contact lenses have also been made out of silicone and other optically suitable flexible materials. The popularity of soft contact lenses is growing rapidly. The major virtues of these lenses are their softness (providing comfort to the wearer), permeability to gases, and their optical suitability. The hydrophilic lenses are particularly useful for ophthalmological applications due to their ability to absorb water with a concomitant swelling to a soft mass of extremely good mechanical strength, their complete transparency, and their ability to retain shape and dimension when equilibrated in a given fluid.
- One very basic problem associated with soft contact lenses is the development of a convenient, safe-and effective method for disinfecting and cleaning them. -The fact that these lenses are hydrophilic (compared with hard contact lensees) makes them a good environment for breeding microbial contamination; this requires that the lenses be well-disinfected prior to each use. The properties of the polymers used in the lenses allows conventional preservatives and antimicrobials, which might otherwise be used for cleaning and disinfecting, to be absorbed and concentrated in the lenses and later released when the contact lenses are on the eye. The release of such antimicrobial and preservative materials is generally much slower than the uptake, thereby allowing them to build up in the lenses. This buildup may eventually affect the physical characteristics of the lenses, including their dimension and color. The net result of this process can be the damaging or staining of the contact lens, itself, and/or harming the sensitive con- junctival or corneal tissue in the eye.
- Hard contact lenses do not absorb appreciable amounts of water (i.e., only from about 0.1 to about 0.4%) and thus the use of conventional preservatives and antimicrobials generally does not present a problem in the hard contact lens field. Disinfecting of soft contact lenses is frequently carried out by boiling the lenses in normal saline, an inconvenient and cumbersome procedure. Furthermore, wearers of soft contact lenses are often warned that solutions designed for hard contact lenses should not be used with soft lenses, since the preservatives in such solutions will be absorbed and even concentrated by the soft lenses and may seriously damage the contact lens and/or the eye of the user.
- Thimerosal (sodium ethylmercurithiosalicylate) and chlorhexidine are well-known preservatives, frequently used in contact lens disinfecting solutions. See, for example, Handbook of Nonprescription Drugs, 5th ed., American Pharmaceutical Association, 1977, pages 236-247, and U.S. Reissue Patent 29,693, Phares, reissued July 4, 1978. The use of certain organic acids as components in contact lens cleaning solutions has been disclosed in the art. Japanese Specification 78-28,922, Allergan Pharmaceuticals, issued August 17, 1978, describes contact lens cleaning solutions containing polyoxyethylene stearate. French Patent 2,400,906, issued March 23, 1979, describes the use of ascorbic acid and sodium ascorbate in contact lens cleaning solutions.
- -C5-C12 fatty acids and fatty acid salts are known to be effective antimicrobial and antifungal agents. Keeney, Bull. Johns Hopkins Hasp. 78, 333 (1946), teaches the use of a 20% aqueous solution of sodium caprylate, at pH 7.4, to successfully treat moniliasis. U.S. Patent 2,466,663, Russ, et al., issued April 5, 1949, discloses aqueous solutions, having pH's between 4.5 and 10.5, containing a mixture of caprylic acid and a caprylic acid salt, especially zinc or sodium caprylate. These solutions are taught to be useful in preventing the growth of molds or fungi in foods and other nutrient media. Theodore, JAMA 143, 226(1950), discloses that the lower fatty acids have been shown to be of value in the treatment of external infections of the eyes. Specifically, sodium propionate was found effective against bacteria causing common occular and fungal infections, including staphylococcus and Pseudomonas aerugnosa. Copending Canadian Patent 1,098,039, Stone, issued March 24, 1981, describes the use of octanoic acid as a broad spectrum antimicrobial agent in intravenous, nutrient and dialysis solutions; these solutions typically contain electrolytes, such as sodium chloride. The antimicrobial benefits of maintaining a solution pH between about 3.5 and 6.0 are taught.
- It has now been discovered that when the C5-C12 fatty acids are used in disinfecting solutions (also referred to as sterilization solutions in the art) for soft contact lenses, these solutions provide broad spectrum antimicrobial activity, compatibility with the hydrophilic soft contact lens material, and very rapid and complete desorption of the antimicrobial agent from the contact lens material, thereby minimizing the eye irritation and sensitization problems discussed above.
- It is, therefore, an object of the present invention to provide an effective cleaning, disinfecting and storing solution for soft contact lenses characterized by rapid and complete desorption of the antimicrobial material from the lens.
- It is a further object of the present invention to formulate aqueous solutions suitable for cleaning, disinfecting and storing hydrophilic soft contact lenses containing C5-C12 fatty acids.
- It is a still further object of the present invention to provide a method for cleaning and disinfecting hydrophilic soft contact lenses utilizing CS-C12 fatty acids.
- Specifically, the present invention relates to aqueous isotonic solutions having a pH between about 3.5 and 6.5, suitable for cleaning, disinfecting and storing hydrophilic soft contact lenses, comprising:
- (a) from about 0.001% to about 3% of a C5-C12 . fatty acid, especially octanoic acid;
- (b) a sufficient amount of at least.one water-soluble salt, compatible with ocular tissue, to provide a solution salt content equivalent to from about 0.5% to about 1.8% sodium chloride;
- (c) from about 0.01% to about 2% of a calcium chelator, especially ethylenediamine tetraacetic acid and its pharmaceutically-acceptable salts; and
- (d) the balance water.
- The present invention also encompasses a method for cleaning and disinfecting hydrophilic soft contact lenses wherein said lenses are contacted with an effective amount of a C5-C12 fatty acid, especially octanoic acid.
- The compositions of the present invention are formulated as aqueous isotonic solutions which contain three basic components: (1) a CS-C12 fatty acid or a mixture of such acids; (2) a water-soluble, ocular tissue- compatible salt; and (3) a calcium chelator. These components are dissolved.iw water which has been prepared in . such a way so as to be compatible for use in the eye (e.g., pyrogen-free water). When formulated and used as described herein, the solutions of the present invention provide the following advantages over the currently-used soft contact lens disinfecting solutions: (1) rapid and broad spectrum cidal activity; (2) rapid and complete desorption_of the antimicrobial agent from the contact lens material, thereby minimizing eye sensitization and irritation problems; and (3) usage flexibility, since the solutions of the present invention may be used interchangeably in both hot and cold sterilization procedures without causing the lenses to turn opaque.
- The phrase "safe and effective amount", as used herein, means sufficient fatty acid component, comprising. at least the minimum lethal concentration in aqueous solution of the free acid form of the particular fatty acid being used, to provide the desired antimicrobial benefit in the context of and under the conditions utilized in the soaking and disinfecting of hydrophilic soft contact lenses, not to exceed an amount which is compatible with the compositions herein and safe for use in conjunction with ocular tissue.
- "Pharmaceutically-acceptable" or "pharmacologically-acceptable", as used herein, means that the fatty acid compound and other ingredients used in the. compositions are suitable for use in contact with the tissue of humans, particularly ocular tissue, without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
- The term "comprising", as used herein, means that various other compatible components including both active and inert ingredients, can be conjointly employed in the compositions of this invention, as long as. the critical fatty acid compounds are used in the manner disclosed. The term "comprising" thus encompasses and includes the more restrictive terms "consisting of" and "consisting essentially of".
- By "compatible" herein is meant that the components of the present invention are capable of being commingled without interacting in a manner which would substantially decrease the efficacy of the fatty acids under ordinary use conditions.
- All percentages and ratios used herein are by weight, unless otherwise specified.
- The fatty acids useful in the present invention include those having from about 5-to about 12 carbon atoms; carboxylic acids outside of this range are significantly- less effective as antimicrobial agents. These materials, themselves, are well-known in the art. For example, octanoic acid is an oily liquid having a boiling point of 239.7°C and a melting point of 16.7°C; it is very. slightly soluble in water (0.068 grams/100 grams at 20°C) and freely soluble in alcohol, chloroform, carbon disulfide, petroleum ether and glacial acetic acid. Octanoic acid may be prepared from 1-heptene, Dupont, et al., Compt. Rend. 240, 628 (1958),- or by the oxidation of octanol, Langenbeck, et al., Ber., 89, 202 (1956).
- The manufacture of octanoic acid is described in U.S. Patent 2,821,532, issued in 1958 and assigned to GAF, and U.S. Patent 3,053,869, issued in 1960 and assigned to Standard Oil of Indiana. See also Fatty Acids, part 1, K.S. Merkley, Editor (Interscience,New York, 2nd Ed., 1960) pages 34-38. Decanoic acid is a crystalline solid having a melting point of 31.4°C; it is practically insoluble in water. See Fatty Acids, part l, supra, pages 34-39. Decanoic acid may be prepared from octyl- bromide, Shishido, et al., J. Am. Chem. Soc. 81, 5817 (1959), and.U.S. Patent 2,918,494, issued in 1959 and assigned to Ethyl Corp.
- It is preferred that the fatty acid component used in the present invention be a C5-C12 non-aromatic carboxylic acid, such as n-pentanoic, n-hexanoic, n-heptanoic, n-octanoic, n-nonanoic, n-decanoic, n-undecanoic, or n-dodecanonic acid. Preferred fatty acid materials for use in the present invention contain from 6 to 10 carbon atoms, with octanoic and decanoic acid being particularly preferred. Mixtures of the above fatty acid materials may also be used, as may salts of the fatty acids, provided that the pH criteria for the compositions, as described below, are met.
- The compositions of the present invention contain from about 0.001% to about 3%, preferably from about 0.01% to about 1.5% of the fatty acid materials. The compositions are formulated to have a pH of no greater than about 6.5 and no less than about 3.5, preferably the pH falls between about 5 and about 6.5. At pH's above this range, the antimicrobial performance of the composition falls off significantly; obviously a pH which is too low (acidic) would not be suitable for use in an ocular context. Compatible acidic or basic ingredients may be used to adjust the pH of the compositions to the desired range.
- The solutions of the present invention must also contain at least one water-soluble salt, compatible with ocular tissue, sufficient in amount to provide a solution salt content equivalent to from about 0.5% to about 1.8% sodium chloride. The purpose of this water-soluble salt is to make the solution isotonic. Hypotonic solutions (for example, tap water) will cause the contact lens to adhere too tightly to the cornea, while a hypertonic solution (for example, excess saline) will result in stinging, lacri- mation and red eyes. Mixtures of water-soluble salts may be used as long as the isotonicity of the solution is maintained. Examples of water-soluble salts useful in the present invention include sodium chloride, sodium citrate, sodium lactate, sodium phosphate, the sodium salts of the fatty acids defined above (such as sodium octanoate), and mixtures thereof, with sodium chloride being especially preferred.
- The compositions of the present invention also contain from about 0.01% to about 2%, preferably from about 0.05% to about 1.5% of a calcium chelator component. This chelating agent is used to prevent metal ions, such as calcium ions, from fixing to the surfaces of the contact lenses and for removing those metal ions which are fixed to the surfaces of the lenses. Buildup of calcium ions on the lenses may cause eye irritation. Useful chelating agents include aminopolycarboxylic acids (such as hydroxyethyl imino diacetic acid, nitrilo triacetic acid, ethylene diamine tetraacetic acid, hydroxyethyl ethylenediamine triacetic acid, and diethylene triamine pentacetic acid), alpha-hydroxy acids (such as citric acid, tartaric acid, and gluconic acid), and condensed phosphates and phosphonates. The preferred chelating agents for use in the present invention are ethylenediamine tetraacetic acid'and pharmaceutically-acceptable salts thereof, especially sodium ethylenediamine tetracetate. Other useful calcium chelating components include ethane-l-hydroxy-l,l-diphos- phonic acid, methane diphosphonic acid, hydroxy methane disphosphonic acid and mixtures thereof.
- Other components conventionally found in contact lens disinfecting and soaking solutions, such as buffers, surfactants and viscosity control agents, may be included in the compositions of the present invention at their are- established usage Ievels. Thus, the compositions may optionally contain from about 0.01% to about 5% of a pharmacologically-acceptable buffer. Examples of ophthalmologically-physiologically acceptable buffers which may be used in the present invention include combinations of boric acid and its sodium salt, phosphoric acid and its sodium salts, citric acid and its sodium salts, lactic acid its sodium salt, amino acids (such as glycine or glutamic acid) and their sodium salts, and maleic acid and its sodium salt. Preferred compositions of the present invention may additionally contain from about 0.01% to about 5% of a pharmacologically-acceptable viscosity control agent, such as polyvinyl alcohol, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, soluble polyhydroxyethyl methacrylate (known as poly hema), polyvinyl pyrollidone, and mixtures thereof.
- The solutions of the present invention may also contain from about 0.01% to about 5% of a pharmacologically- and ophthalmologically-acceptable surfactant, particularly a nonionic surfactant. These surfactants are especially useful when the solutions are formulated to clean the lenses as well as to sterilize them. The surfactants which may be employed in the present invention must be completely miscible with water at the concentrations employed and must provide a clear solution. In addition, the surfactant must be stable under the disinfecting conditions, must not act adversely with the soft contact lens, nor with other materials present in the solution and, finally, must not irritate the eye. The surfactant preferably is not absorbed by the soft contact lens material, while being capable of solublizing the proteinaceous and lipid materials adsorbed onto the lens and, further, preventing redeposition during sterilization and subsequent storage. Useful nonionic surfactants are well-kndwn in the art and include, but are not limited to, hydroxyalkylated and polyoxyalkylated surfactants, such as n-hydroxyalkylated carboxamides of fatty acids of from 10 to 18 carbon atoms, preferably of from 12 to 14 carbon atoms, and having 0 or 1 sites of olefinic unsaturation as the only unsaturation, preferably being saturated. These compounds will normally contain two hydroxyalkyl groups of from 2 to 3 carbon atoms which.may be the same or different.
- The polyoxyalkylated nonionic surfactants may be solely comprised of ethoxy or propoxy groups or may have a polyoxyalkylene chain bonded directly or indirectly to an aliphatic chain of from 10 to 18 carbon atoms. The alkyl- containing group may be a sorbitan ester, an alkylphenyl, alkyl, carboxylic acid, or the like. The polyoxyalkylene chain may be a homo-oligomer or co-oligomer, with the homo-oligomer normally being ethyleneoxy groups and the co-oligomer being a random or block co-oligomer of ethyleneoxy and propyleneoxy groups. These various nonionic detergents are commercially available under a wide variety of tradenames, such as Tween, Igepal, Pluronic, Brij, and Myrj.. The alkyleneoxy chains will generally range on the average of from about 5 to about 60 oxyalkylene units. Ampholytic surfactants, such as betaines having an aliphatic carbon chain bonded to nitrogen of from about 10 to 18 carbon atoms, preferably from about 10 to 14 carbon atoms, may also be used herein. Particularly preferred surfactants for use in the present invention include polyoxyethylenes, octylphenoxy polyethoxy ethanols, polysorbates and mixtures thereof.
- The present invention also encompasses a method for cleaning and disinfecting hydrophilic soft contact lenses Wherein the lenses are contacted with a safe and effective amount of the C S-C 12 fatty acids. In practicing this method, the fatty acids will generally be in the form of an aqueous solution having a concentration of from about 1 to about 200, preferably from about 1 to about 175, millimoles of a mixture of the free fatty acid and the carboxylate (anionic) salt per liter. The microbiocidal activity of the C5-C12 carboxylate antimicrobials used herein is directly related to the presence of their respective free acids in solution. The concentration of free carboxylic acid in solution, as opposed to carboxylate salt (anionic) form, is a function of the pH of the solution. The carboxylic acid salts can be used herein, but only as long as the pH of the solution is in the acid range so that the minimum lethal concentration (MLC) of free acid is present. Accordingly, the amount of acid or acid salt used will vary somewhat with the pH. The amount of a given acid salt or acid which will provide the MLC at a given pH will depend on the pKa of the acid. Of course, knowing the pKa, the MLC of the particular acid and the solution pH, the amount of any C5-C12 acid or acid salt to be used is easily calculated. Representative MLC values are as follows: C5 (0.11 M) ; C6 (30 mM); C7 (9 mM); C8 . (3 mM); and C9 (1mM). The compositions, described above, are preferred for use in this method. Generally, the contact lenses are contacted with the fatty acid components for periods ranging between about 5 minutes and about 12 hours, although under some circumstances, longer or shorter periods may be utilized.
- The following non-limiting examples illustrate the compositions and the methods of the present invention.
-
- The following quantities of materials were measured out and added to a 100 milliliter volumetric flask: 0.943 grams of sodium octanoate; 0.696 grams of monobasic sodium phosphate; 0.123 grams of dibasic sodium phosphate; 0.1 gram ethylenediamine tetraacetic acid, disodium salt; and 0.187 grams of sodium chloride. These materials were dissolved in 100 milliliters of distilled water. The resulting solution had a pH of 6.0 when measured at a temperature of 23°C.
- Compositions of the present invention may also be formulated by adding about 0.5%.of a surfactant selected from polyoxyethylene, polysorbate 80, octylphenoxy (oxyethylene) ethanol,, and mixtures thereof to the composition described above. A viscosity control agent selected from polyvinyl alcohol, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, soluble poly hema, polyvinyl pyrollidone, and mixtures thereof may also be added to the formulation given above at a level of about 0.5%.
- Compositions of the present invention may also be formulated by replacing the sodium octanoate, in the compositions described above, with an equivalent amount of a fatty acid selected from sodium pentanoate, sodium pentanoate, sodium hexanoate, sodium heptanoate, sodium nonanoate, sodium decanoate, sodium undecanoate, or sodium dodecanaote.
- The level of octanoate absorbed by Bausch & Lomb Soflens contact lenses from disinfecting solutions of the present invention, as well as the rate at which the octanoate is desorbed from the lenses was determined by the procedure described below.
- The test solution used in this procedure was that described in Example I, except that the sodium octanoate was labeled using carbon-14, having a radiochemical purity of greater than 98.5%, a chemical purity of greater than 99%, and a specific activity of 164 mCi/gram. 35 Milliliters of the test solution was prepared. Four scintillation vials were filled with 5.03 ±0.03.milliliters of this solution. Another four vials were filled with 2.51 ±0.03 milliliters of the solution.Two vials from each set of four vials were set aside for radioassay. The remaining four vials each had a contact lens (Bausch & Lomb Soflens) submersed in it. After 4 hours, each lens was removed from its vial with fine forceps. The lenses were gently touched to the inside walls of the vial to remove excess fluid and were not rinsed. The lenses were then immediately transferred to,vials containing 2.5 milliliters of a 00.9% sodium chloride solution and gently swirled.
-
- All vials utilized in this process were submitted for radioassay. Two unused 2.5 milliliter samples of the 0.9% sodium chloride solution were also submitted for radioassay. The lenses were retained in the vials of the final transfer and were submitted for radioassay.
- If the sum of the radioactivity from the desorption vials (saline solutions) plus the initial sorption vial (C-14 octanoic acid solution) did not add up to at least 95% of the radioactivity of the unused C14 octanoic acid vials, then an additional transfer of the lens was performed within a week of the beginning of the experiment. The vial used for lens storage up to that time was then submitted for radioassay..If this radioactivity did not bring the total radioactivity up to at least 95% recovery, then the lens used for that sequence of transfer.was submitted in the storage vial containing 2.5 milliliters of 0.9% sodium chloride. If submission of the lenses was not required for radioactivity balance data, the . lenses were submitted for radioassay to demonstrate negligible radioactivity remaining in them.
- The procedure above was repeated on four samples and the results were averaged over thes four runs. The average percent sodium carbon-14 octanoate remaining in the contact lens material as a function of desorption time is summarized in the table below.
- Average sodium octanoate absorbed per lens = 0.546 mg ± 0.031 mg
-
- Using a procedure similar to that described in Example II and the composition described in Example I, the desorption characteristics of a composition of the present invention were determined using a variety of hydrophilic soft contact lens materials. The lenses tested were Soflens made from a Polymacon polymer; Hydron made'from a Polymacon polymer; Durasoft, made from Phemfilcon A polymer; AO Soft made from Tetrafilcon A polymer; and Hydrocurve II, made from Bufilcon A polymer.
- -The sorption and desorption procedures described in Example II were followed in the. present test, except for the Bausch & Lomb Soflens soft contact lenses. Six of the Bausch & Lomb lenses were tested. Two lenses were tested following the usual procedure, except that the lens transfer schedule was not followed; these two lenses were instead desorbed with the following transfer schedule: 5 minutes, 5 minutes, 10 minutes, and 30 minutes. Another pair of soft lenses spent seven days in the sorption vial rather than only four hours. After seven days, these lenses were desorbed according to the usual desorption schedule. The remaining two lenses were placed with test solution in a Bausch &. 'Lomn Lensgard lens carrying case according to the manufacturer's recommended procedures. This was done after the lenses had first soaked for four hours in the test salution. The lenses and solutions in the Lensgard case were subjected to heat sterilization with the Bausch & Lomb Disinfecting Unit II according to the manufacturer's recommended procedures. The unit was allowed to cool and stand overnight and the lenses were desorbed approximately 24 hours after the initial sorption began, using the usual desorption transfer schedule. The test solution was not retained and submitted for radioassay for the final two lenses because of expected evaporative losses in the heat sterilization process. The above treatments were shown to have no significant effect on the time course or completeness-of the desorption from the Bausch & Lomb lenses.
-
- All lenses tested, with the exception of Durasoft, gave a plateau in a desorption curve by the one hour time point showing complete release. Durasoft, a nonpolar acrylic, had slower kinetics resulting in complete release as well. In all cases, the desorption exhibited by the composition of the present invention was both complete and rapid when compared with that of chlorhexidine (as described in Example II), an antimicrobial agent conventionally used in contact lens disinfecting solutions.
- Substantially similar results (i.e., results superior to conventional chlorhexidine-containing disinfecting solutions) are obtained when the sodium octanoate used in the above example is replaced, in whole or in part, by an equivalent amount of n -entanoic acid, n-hexanoic acid, n-heptanoic acid, n-octanoic acid, n-nonanoic acid, n-decanoic acid, n-undecanoic acid, n-dodecanoic acid, the sodium salt of these acids, or mixtures thereof. Similar results are also obtained where the sodium chloride, used to obtain isotonicity in the solution, is replaced in whole or in part with sodium citrate, sodium lactate, sodium phosphate, and mixtures thereof. Substantially similar results are also obtained where the buffer portion of the solution (i.e., the mono-and dibasic sodium phosphate components) are replaced in whole or in part with combinations of boric acid and its sodium salt, citric acid and its sodium salts, lactic acid and its sodium salt, glycine or glutamic acid and their. sodium salts, maleic acid and its sodium salt, or.mixtures thereof. The ethylene diamine tetraacetic acid, disodium salt, may also be replaced in whole or in part with ethane-1-hydroxy-1,1-diphosphonic acid, methane diphosphonic acid, hydroxymethane diphosphonic acid and mixtures thereof, yielding similar results.
- Using the procedures described in the U.S. Food and Drug Administration, Bureau of Medical Devices' 1980 monograph on class II contact lens product guidelines for contact lens solution testing, the efficacy of a 4mM octanoic acid solution of the present invention was determined. The solution tested had a pH of 6.0 and contained the following components per 500 ml. of distilled water:
- The antimicrobial efficacy of the composition was expressed in terms of D-values against a range of microorganisms specified by the U.S. FDA as'those which a class II contact lens solution should be effective against. A D-value is the time required to kill 90% of a population of microorganisms. In this-study the D-value was calculated from the amount of time required for the product to completely kill a population of about 105 organisms/ml. The results of this study are summarized below.
- By way of comparison, a commercial contact lens disinfecting solution sold by Allergan, under the same testing conditions, had D-values greater than 10 minutes against Serratia marcescens and greater than 2 hours against Aspergillus fumagatis spores. Direct efficacy testing of the above solution against contaminated lenses revealed that the lenses were decontaminated in two hours or less, while the commercially-available solutions tested required at least about 4 hours for comparable performance. Moreover, the commercial solutions yielded only a slight or no decrease in the number of viable A. fumagatis spores after a 4 hour exposure. The antibacterial effectiveness of the currently-available soft contact lens cold disinfection solutions,particularly useful for comparison with the test results herein, is described in Sibley, Soft Lens Cold Disinfection Solutions: A Comparative Study, Cbntact Lens Forum, December, 1981, pages 41 et seq.
- Substantially similar results are obtained when the sodium octanoate used in the above example is replaced, in whole or in part, by an equivalent amount of n-pentanoic acid, n-hexanoic acid, n-heptanoic acid, n-octanoic acid, n-nonanoic acid, n-decanoic acid, n-undecanoic acid, n-dodecanoic acid, the sodium salts of these acids, or mixtures thereof. Similar results are also obtained where the sodium chloride, used to obtain isotonicity in the solution, is replaced in whole or in part, with sodium citrate, sodium lactate, sodium phosphate, and mixtures thereof. Substantially similar results are also obtained where the buffer portion of the solution (i.e., the mono-and dibasic sodium phosphate components) are replaced in whole or in part with combinations of boric acid and its sodium salt, citric acid and its sodium salts, lactic acid and its sodium salt, glycine or glutamic acid and their sodium salt, maleic acid and its sodium salt, or mixtures thereof. The ethylene diamine tetraacetic acid, disodium salt, may also be replaced in whole or in part with ethane-l-hydroxy-l,l-diphosphonic acid, methane diphosphonic acid, hydroxymethane diphosphonic acid and mixtures thereof, yielding similar results.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT82201665T ATE15447T1 (en) | 1982-01-13 | 1982-12-28 | DISINFECTION SOLUTIONS FOR SOFT CONTACT LENSES. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US339218 | 1982-01-13 | ||
US06/339,218 US4410442A (en) | 1982-01-13 | 1982-01-13 | Disinfecting solutions for hydrophilic contact lenses |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0083820A1 true EP0083820A1 (en) | 1983-07-20 |
EP0083820B1 EP0083820B1 (en) | 1985-09-11 |
Family
ID=23328027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP82201665A Expired EP0083820B1 (en) | 1982-01-13 | 1982-12-28 | Disinfecting solutions for hydrophilic contact lenses |
Country Status (17)
Country | Link |
---|---|
US (1) | US4410442A (en) |
EP (1) | EP0083820B1 (en) |
JP (1) | JPS58171499A (en) |
AR (1) | AR231802A1 (en) |
AT (1) | ATE15447T1 (en) |
AU (1) | AU549420B2 (en) |
BR (1) | BR8300127A (en) |
CA (1) | CA1186194A (en) |
DE (1) | DE3266255D1 (en) |
DK (1) | DK12183A (en) |
ES (1) | ES518918A0 (en) |
FI (1) | FI830104L (en) |
GR (1) | GR81931B (en) |
IE (1) | IE54499B1 (en) |
NZ (1) | NZ203015A (en) |
PH (1) | PH18951A (en) |
ZA (1) | ZA83221B (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3333443A1 (en) * | 1983-09-16 | 1985-03-28 | B. Braun Melsungen Ag, 3508 Melsungen | DISINFECTANT CONCENTRATES BASED ON SHORT-CHAIN FATTY ACIDS |
DE3344328A1 (en) * | 1983-12-08 | 1985-06-20 | Diversey Gmbh, 6000 Frankfurt | ANTIMICROBIAL AGENT WITH WATER |
EP0155505A1 (en) * | 1984-03-21 | 1985-09-25 | Ciba-Geigy Ag | Cleaning kit for contact lenses, method and apparatus therefor |
GB2252421A (en) * | 1990-12-31 | 1992-08-05 | Tchelva Ramanathan | Cleaning soft contact lenses |
WO1992021238A1 (en) * | 1991-06-04 | 1992-12-10 | Ecolab Inc. | Sanitizing compositions |
WO1993002715A1 (en) * | 1991-08-02 | 1993-02-18 | Paulo Ferrara De Almeida Cunha | Powdered product for cleaning gelatinous contact lens (hydrophilic) |
US5234719A (en) * | 1991-06-04 | 1993-08-10 | Ecolab Inc. | Food additive sanitizing compositions |
US5336500A (en) * | 1991-06-04 | 1994-08-09 | Ecolab Inc. | Sanitizing composition comprising a blend of aromatic and polyunsaturated carboxylic acid |
US5409713A (en) * | 1993-03-17 | 1995-04-25 | Ecolab Inc. | Process for inhibition of microbial growth in aqueous transport streams |
US5436008A (en) * | 1992-12-11 | 1995-07-25 | Ecolab Inc. | Sanitizing compositions |
US5578134A (en) * | 1994-04-19 | 1996-11-26 | Ecolab Inc. | Method of sanitizing and destaining tableware |
US5683724A (en) * | 1993-03-17 | 1997-11-04 | Ecolab Inc. | Automated process for inhibition of microbial growth in aqueous food transport or process streams |
US6257253B1 (en) | 1994-04-19 | 2001-07-10 | Ecolab Inc. | Percarboxylic acid rinse method |
US6302968B1 (en) | 1994-04-19 | 2001-10-16 | Ecolab Inc. | Precarboxylic acid rinse method |
WO2013032464A1 (en) * | 2011-08-31 | 2013-03-07 | Organic Medical Ventures, L.L.C. | Transdermal venous access locking solutions |
US9072296B2 (en) | 2009-03-26 | 2015-07-07 | Organic Medical Ventures, L.L.C. | Transdermal venous access locking solutions |
US9427498B2 (en) | 2009-03-26 | 2016-08-30 | Organic Medical Ventures, L.L.C. | Syringe treated with transdermal venous access locking solutions and method of treating the syringe |
US9433209B2 (en) | 2009-03-26 | 2016-09-06 | Organic Medical Ventures, L.L.C. | Transdermal venous access locking solutions |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60159721A (en) * | 1984-01-31 | 1985-08-21 | Nippon Contact Lens Seizo Kk | Cleaner for contact lens |
IN160430B (en) * | 1984-03-18 | 1987-07-11 | Alcide Corp | |
US5185161A (en) * | 1984-03-21 | 1993-02-09 | Alcide Corporation | Disinfection method and composition therefor |
US4986990A (en) * | 1984-03-21 | 1991-01-22 | Alcide Corporation | Disinfection method and composition therefor |
US4808239A (en) * | 1984-12-28 | 1989-02-28 | Alcon Laboratories, Inc. | Method of cleaning contact lens using compositions containing polyether carboxylic acid surfactant |
US4599195A (en) * | 1984-12-28 | 1986-07-08 | Alcon Laboratories, Inc. | Solution and method for removing protein, lipid, and calcium deposits from contact lenses |
CA1331559C (en) | 1986-04-21 | 1994-08-23 | Jon Joseph Kabara | Antimicrobial preservative compositions and methods |
CA1302280C (en) | 1986-04-21 | 1992-06-02 | Jon Joseph Kabara | Topical antimicrobial pharmaceutical compositions and methods |
US5208257A (en) * | 1986-04-21 | 1993-05-04 | Kabara Jon J | Topical antimicrobial pharmaceutical compositions and methods |
US4891216A (en) * | 1987-04-14 | 1990-01-02 | Alcide Corporation | Disinfecting compositions and methods therefor |
US5505953A (en) * | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
US5234703A (en) * | 1992-10-31 | 1993-08-10 | Guthery B Eugene | Disinfecting product and process |
NZ256543A (en) * | 1992-11-09 | 1997-10-24 | West Agro Inc | Sanitizer/biocidal dilutable concentrate comprising germicidal fatty acids |
AU3070395A (en) * | 1994-07-22 | 1996-02-22 | Alcon Laboratories, Inc. | Use of low molecular weight amino acids in ophthalmic compositions |
TW266267B (en) * | 1994-08-23 | 1995-12-21 | Ciba Geigy | Process for sterilizing articles and providing sterile storage environments |
EP0733918B1 (en) * | 1995-03-24 | 2003-07-30 | Ocular Research of Boston, Inc. | Hydrogel lens pre-coated with lipid layer |
US5618554A (en) * | 1995-06-07 | 1997-04-08 | Kimberly-Clark Corporation | Inhibition of exoprotein using amine compositions in absorbent article and method thereof |
US5612045A (en) * | 1995-06-07 | 1997-03-18 | Kimberly-Clark Corporation | Inhibition of exoprotein in absorbent article |
US5685872A (en) * | 1995-06-07 | 1997-11-11 | Kimberly-Clark Worldwide, Inc. | Inhibition of exoprotein using amide compositions in absorbent article |
US5905065A (en) * | 1995-06-27 | 1999-05-18 | The Procter & Gamble Company | Carpet cleaning compositions and method for cleaning carpets |
US7109241B1 (en) * | 2000-10-02 | 2006-09-19 | Ecolab, Inc. | Antimicrobial compositions formulated for use in cold temperature conditions and methods of use thereof |
JP2003137775A (en) * | 2001-10-31 | 2003-05-14 | Menicon Co Ltd | Ophthalmic composition |
US6949590B2 (en) * | 2002-01-10 | 2005-09-27 | University Of Washington | Hydrogels formed by non-covalent linkages |
TWI322828B (en) | 2002-12-23 | 2010-04-01 | Alcon Inc | Use of multifunctional surface active agents to clean contact lenses |
US20050277562A1 (en) * | 2004-06-14 | 2005-12-15 | Erning Xia | Compositions for cleaning and treating surgical devices |
US20080102095A1 (en) | 2006-10-31 | 2008-05-01 | Kent Young | Acidic processes to prepare antimicrobial contact lenses |
US9752105B2 (en) | 2012-09-13 | 2017-09-05 | Ecolab Usa Inc. | Two step method of cleaning, sanitizing, and rinsing a surface |
US20140308162A1 (en) | 2013-04-15 | 2014-10-16 | Ecolab Usa Inc. | Peroxycarboxylic acid based sanitizing rinse additives for use in ware washing |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2466663A (en) * | 1944-10-20 | 1949-04-05 | Ward Baking Co | Fungicide containing caprylic acid and its salt |
EP0022289A1 (en) * | 1979-06-29 | 1981-01-14 | THE PROCTER & GAMBLE COMPANY | Antimicrobial polymer compositions and use thereof in medical devices |
US4259202A (en) * | 1979-02-27 | 1981-03-31 | Toyo Contact Lens Co., Ltd. | Cleaning and preservative solution for contact lenses |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2841526A (en) * | 1956-06-04 | 1958-07-01 | R J Strasenburgh Co | Fatty acid-resin adsorption product |
US3171752A (en) * | 1962-07-11 | 1965-03-02 | Burton Parsons Chemicals Inc | Contact lens treating solution |
US3743519A (en) * | 1970-07-30 | 1973-07-03 | Gen Foods Corp | Acid stabilization of meat based foods |
US3689673A (en) | 1970-11-10 | 1972-09-05 | Barnes Hind Pharm Inc | The process of soaking and sterilizing hydrophilic soft contact lenses with chlorhexidene |
US4046706A (en) * | 1976-04-06 | 1977-09-06 | Flow Pharmaceuticals, Inc. | Contact lens cleaning composition |
FR2400906A1 (en) | 1978-08-22 | 1979-03-23 | Evers Hans | Disinfecting and cleaning contact lenses without allergic reaction - with cold soln. contg. ene:diol redox system, water-soluble oxidising agent and opt. heavy metal salt catalyst |
US4323467A (en) * | 1980-11-24 | 1982-04-06 | Syntex (U.S.A.) Inc. | Contact lens cleaning, storing and wetting solutions |
-
1982
- 1982-01-13 US US06/339,218 patent/US4410442A/en not_active Expired - Fee Related
- 1982-12-28 EP EP82201665A patent/EP0083820B1/en not_active Expired
- 1982-12-28 DE DE8282201665T patent/DE3266255D1/en not_active Expired
- 1982-12-28 AT AT82201665T patent/ATE15447T1/en not_active IP Right Cessation
-
1983
- 1983-01-11 CA CA000419231A patent/CA1186194A/en not_active Expired
- 1983-01-11 GR GR70233A patent/GR81931B/el unknown
- 1983-01-11 PH PH28377A patent/PH18951A/en unknown
- 1983-01-12 ES ES518918A patent/ES518918A0/en active Granted
- 1983-01-12 IE IE64/83A patent/IE54499B1/en unknown
- 1983-01-12 AU AU10319/83A patent/AU549420B2/en not_active Ceased
- 1983-01-12 BR BR8300127A patent/BR8300127A/en unknown
- 1983-01-12 AR AR291842A patent/AR231802A1/en active
- 1983-01-12 FI FI830104A patent/FI830104L/en not_active Application Discontinuation
- 1983-01-13 DK DK12183A patent/DK12183A/en not_active Application Discontinuation
- 1983-01-13 JP JP58002919A patent/JPS58171499A/en active Pending
- 1983-01-13 ZA ZA83221A patent/ZA83221B/en unknown
- 1983-01-13 NZ NZ203015A patent/NZ203015A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2466663A (en) * | 1944-10-20 | 1949-04-05 | Ward Baking Co | Fungicide containing caprylic acid and its salt |
US4259202A (en) * | 1979-02-27 | 1981-03-31 | Toyo Contact Lens Co., Ltd. | Cleaning and preservative solution for contact lenses |
EP0022289A1 (en) * | 1979-06-29 | 1981-01-14 | THE PROCTER & GAMBLE COMPANY | Antimicrobial polymer compositions and use thereof in medical devices |
Non-Patent Citations (1)
Title |
---|
H. IPPEN: INDEX PHARMACORUM, 170, EDITION 1, Georg Thieme Verlag, Stuttgart, DE. * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3333443A1 (en) * | 1983-09-16 | 1985-03-28 | B. Braun Melsungen Ag, 3508 Melsungen | DISINFECTANT CONCENTRATES BASED ON SHORT-CHAIN FATTY ACIDS |
DE3344328A1 (en) * | 1983-12-08 | 1985-06-20 | Diversey Gmbh, 6000 Frankfurt | ANTIMICROBIAL AGENT WITH WATER |
EP0155505A1 (en) * | 1984-03-21 | 1985-09-25 | Ciba-Geigy Ag | Cleaning kit for contact lenses, method and apparatus therefor |
GB2252421A (en) * | 1990-12-31 | 1992-08-05 | Tchelva Ramanathan | Cleaning soft contact lenses |
WO1992021238A1 (en) * | 1991-06-04 | 1992-12-10 | Ecolab Inc. | Sanitizing compositions |
US5234719A (en) * | 1991-06-04 | 1993-08-10 | Ecolab Inc. | Food additive sanitizing compositions |
US5336500A (en) * | 1991-06-04 | 1994-08-09 | Ecolab Inc. | Sanitizing composition comprising a blend of aromatic and polyunsaturated carboxylic acid |
US5419908A (en) * | 1991-06-04 | 1995-05-30 | Ecolab Inc. | Sanitizing composition comprising a blend of aromatic and polyunsaturated carboxylic acids |
WO1993002715A1 (en) * | 1991-08-02 | 1993-02-18 | Paulo Ferrara De Almeida Cunha | Powdered product for cleaning gelatinous contact lens (hydrophilic) |
US5436008A (en) * | 1992-12-11 | 1995-07-25 | Ecolab Inc. | Sanitizing compositions |
US5674538A (en) * | 1993-03-17 | 1997-10-07 | Ecolab Inc. | Process for inhibition of microbial growth in aqueous food transport or process streams |
US5409713A (en) * | 1993-03-17 | 1995-04-25 | Ecolab Inc. | Process for inhibition of microbial growth in aqueous transport streams |
US5683724A (en) * | 1993-03-17 | 1997-11-04 | Ecolab Inc. | Automated process for inhibition of microbial growth in aqueous food transport or process streams |
US5578134A (en) * | 1994-04-19 | 1996-11-26 | Ecolab Inc. | Method of sanitizing and destaining tableware |
US6257253B1 (en) | 1994-04-19 | 2001-07-10 | Ecolab Inc. | Percarboxylic acid rinse method |
US6302968B1 (en) | 1994-04-19 | 2001-10-16 | Ecolab Inc. | Precarboxylic acid rinse method |
US9427498B2 (en) | 2009-03-26 | 2016-08-30 | Organic Medical Ventures, L.L.C. | Syringe treated with transdermal venous access locking solutions and method of treating the syringe |
US9072296B2 (en) | 2009-03-26 | 2015-07-07 | Organic Medical Ventures, L.L.C. | Transdermal venous access locking solutions |
US9380780B2 (en) | 2009-03-26 | 2016-07-05 | Organic Medical Ventures, L.L.C. | Transdermal venous access locking solutions |
US9433209B2 (en) | 2009-03-26 | 2016-09-06 | Organic Medical Ventures, L.L.C. | Transdermal venous access locking solutions |
CN104159446A (en) * | 2011-08-31 | 2014-11-19 | 系统医疗风险有限责任公司 | Transdermal venous access locking solutions |
WO2013032464A1 (en) * | 2011-08-31 | 2013-03-07 | Organic Medical Ventures, L.L.C. | Transdermal venous access locking solutions |
AU2011375794B2 (en) * | 2011-08-31 | 2016-09-15 | Organic Medical Ventures, L.L.C. | Transdermal venous access locking solutions |
CN104159446B (en) * | 2011-08-31 | 2016-10-26 | 系统医疗风险有限责任公司 | Transdermal venous channel lock solution |
EA030684B1 (en) * | 2011-08-31 | 2018-09-28 | ОРГАНИК МЕДИКАЛ ВЕНЧЕРЗ, Эл.Эл.Си. | Transdermal venous access locking solutions |
Also Published As
Publication number | Publication date |
---|---|
JPS58171499A (en) | 1983-10-08 |
EP0083820B1 (en) | 1985-09-11 |
ES8406882A1 (en) | 1984-08-16 |
ATE15447T1 (en) | 1985-09-15 |
IE54499B1 (en) | 1989-10-25 |
US4410442A (en) | 1983-10-18 |
PH18951A (en) | 1985-11-14 |
DE3266255D1 (en) | 1985-10-17 |
NZ203015A (en) | 1985-12-13 |
IE830064L (en) | 1983-07-13 |
FI830104A0 (en) | 1983-01-12 |
GR81931B (en) | 1984-12-12 |
AU549420B2 (en) | 1986-01-23 |
FI830104L (en) | 1983-07-14 |
ZA83221B (en) | 1983-10-26 |
BR8300127A (en) | 1983-10-04 |
AR231802A1 (en) | 1985-03-29 |
DK12183A (en) | 1983-07-14 |
DK12183D0 (en) | 1983-01-13 |
CA1186194A (en) | 1985-04-30 |
ES518918A0 (en) | 1984-08-16 |
AU1031983A (en) | 1983-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0083820B1 (en) | Disinfecting solutions for hydrophilic contact lenses | |
US4046706A (en) | Contact lens cleaning composition | |
AU695042B2 (en) | Saline solution for treating contact lenses | |
EP1102602B1 (en) | Contact lens and ophthalmic solutions | |
JPH0254804B2 (en) | ||
JPS6185301A (en) | Disinfectant preserving solution for contact lens | |
CA1150907A (en) | Contact lens cleaning and storage solution | |
EP1416975B1 (en) | Disinfecting and cleansing system for contact lenses | |
US6528464B1 (en) | Composition and method for inhibiting uptake of biguanide antimicrobials by hydrogels | |
US5820696A (en) | Method of cleaning and disinfecting contact lens | |
US4543200A (en) | Contact lens preservative system cleaner and method | |
US4510065A (en) | Soft contact lens preservative system, prophylactic cleaner and method | |
JPH0816042B2 (en) | Liquid for contact lenses | |
CA2473935A1 (en) | Composition for treating contact lenses | |
CA2470003A1 (en) | Composition for treating contact lenses in the eye | |
EP1706473B1 (en) | Nonionic surfactant containing compositions for cleaning contact lenses | |
JPH09206362A (en) | Sterilizing and cleaning composition for contact lens and sterilizing and cleaning method for contact lens using the same | |
IE920838A1 (en) | Contact lens disinfecting compositions | |
AU2004305535A1 (en) | Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions | |
EP0175490A2 (en) | Contact lens treatment compositions and their uses | |
CA1247974A (en) | Contact lens cleaner and method | |
AU2006202392A1 (en) | Composition for treating contact lenses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19840114 |
|
ITF | It: translation for a ep patent filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 15447 Country of ref document: AT Date of ref document: 19850915 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3266255 Country of ref document: DE Date of ref document: 19851017 |
|
ET | Fr: translation filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19851213 Year of fee payment: 4 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19851231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19851231 Year of fee payment: 4 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Effective date: 19861228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19861229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19861231 Ref country code: CH Effective date: 19861231 Ref country code: BE Effective date: 19861231 |
|
BERE | Be: lapsed |
Owner name: THE PROCTER & GAMBLE CY Effective date: 19861231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19870701 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19870831 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19870901 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19881122 |
|
EUG | Se: european patent has lapsed |
Ref document number: 82201665.5 Effective date: 19870917 |